For vaptans, as for life, balance is better
- PMID: 33125825
- DOI: 10.1002/ejhf.2042
For vaptans, as for life, balance is better
Comment on
-
Cardiac output improvement by pecavaptan: a novel dual-acting vasopressin V1a/V2 receptor antagonist in experimental heart failure.Eur J Heart Fail. 2021 May;23(5):743-750. doi: 10.1002/ejhf.2001. Epub 2020 Oct 9. Eur J Heart Fail. 2021. PMID: 32946151 Free PMC article.
Similar articles
-
Vasopressin antagonists in heart failure.Curr Heart Fail Rep. 2004 Dec;1(4):190-6. doi: 10.1007/s11897-004-0008-5. Curr Heart Fail Rep. 2004. PMID: 16036044 Review.
-
Clinical review: the use of vaptans in clinical endocrinology.J Clin Endocrinol Metab. 2013 Apr;98(4):1321-32. doi: 10.1210/jc.2012-4082. Epub 2013 Feb 11. J Clin Endocrinol Metab. 2013. PMID: 23401044 Review.
-
[Current options of treatment of hyponatremia].Vnitr Lek. 2016 Winter;62 Suppl 6:97-101. Vnitr Lek. 2016. PMID: 28124939 Czech.
-
Vasopressin receptor antagonists in the management of acute heart failure.Expert Opin Investig Drugs. 2005 May;14(5):593-600. doi: 10.1517/13543784.14.5.593. Expert Opin Investig Drugs. 2005. PMID: 15926866 Review.
-
Tolvaptan in Acute Heart Failure: Time to Move On.J Am Coll Cardiol. 2017 Mar 21;69(11):1407-1408. doi: 10.1016/j.jacc.2016.09.005. Epub 2016 Sep 18. J Am Coll Cardiol. 2017. PMID: 27654853 No abstract available.
References
-
- Cuffe MS, Califf RM, Adams KF, Benza R, Bourge R, Colucci WS, Massie BM, O'Connor CM, Pina I, Quigg R, Silver MA, Gheorghiade M; Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) Investigators. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 2002;287:1541-1547.
-
- O'Connor CM, Starling RC, Hernandez AF, Armstrong PW, Dickstein K, Hasselblad V, Heizer GM, Komajda M, Massie BM, McMurray JJ, Nieminen MS, Reist CJ, Rouleau JL, Swedberg K, Adams KF Jr, Anker SD, Atar D, Battler A, Botero R, Bohidar NR, Butler J, Clausell N, Corbalán R, Costanzo MR, Dahlstrom U, Deckelbaum LI, Diaz R, Dunlap ME, Ezekowitz JA, Feldman D, Felker GM, Fonarow GC, Gennevois D, Gottlieb SS, Hill JA, Hollander JE, Howlett JG, Hudson MP, Kociol RD, Krum H, Laucevicius A, Levy WC, Méndez GF, Metra M, Mittal S, Oh BH, Pereira NL, Ponikowski P, Tang WH, Tanomsup S, Teerlink JR, Triposkiadis F, Troughton RW, Voors AA, Whellan DJ, Zannad F, Califf RM. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 2011;365:32-43.
-
- Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K, Rocha R, Braunwald E; PIONEER-HF Investigators. Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med 2019;380:539-548.
-
- Domanski M, Norman J, Pitt B, Haigney M, Hanlon S, Peyster E; Studies of Left Ventricular Dysfunction. Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 2003;42:705-708.
-
- Goldsmith SR, Gheorghiade M. Vasopressin antagonism in heart failure. J Am Coll Cardiol 2005;46:1785-1791.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical